UGT1A4

UDP-glucuronosyltransferase 1A4 · P22310 · UGT1A4 on Sugi Atlas →

333 patent compounds predicted against UGT1A4, 264 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Anastrozole (SCHEMBL9726)	1.00	1/20
Anastrozole (SCHEMBL177942)	1.00	1/20
Anastrozole (SCHEMBL27927481)	1.00	1/20
Anastrozole (SCHEMBL3172308)	0.97	1/20
Anastrozole (SCHEMBL5917785)	0.97	1/20
Anastrozole (SCHEMBL28771766)	0.97	1/20
SCHEMBL10324455	0.92	1/20
Anastrozole (SCHEMBL13323739)	0.90	1/20
SCHEMBL8059026	0.87	1/20
Anastrozole (SCHEMBL354747)	0.85	1/20
SCHEMBL12908863	0.85	1/20
Anastrozole (SCHEMBL13323725)	0.84	1/20
Anastrozole (SCHEMBL4727358)	0.83	1/20
SCHEMBL937176	0.82	1/20
SCHEMBL8059020	0.82	1/20
SCHEMBL8059058	0.82	1/20
SCHEMBL10172609	0.82	1/20
SCHEMBL10222027	0.82	1/20
SCHEMBL12908861	0.82	1/20
SCHEMBL10061874	0.81	1/20

Clinical trials — most relevant to UGT1A4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy	PHASE4	COMPLETED
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer	PHASE3	COMPLETED
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial	PHASE3	UNKNOWN
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma	PHASE1/PHASE2	RECRUITING
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer	PHASE2	COMPLETED
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma	PHASE1/PHASE2	RECRUITING
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	PHASE2	ACTIVE_NOT_RECRUITING
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours	PHASE1	UNKNOWN
Cotinine Metabolism in Infants and Children	PHASE1	COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin	PHASE1	COMPLETED
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors	PHASE1	UNKNOWN
A Research Study on Etavopivat in Participants With and Without Liver Disease	PHASE1	COMPLETED
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
Study of NK012 in Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Study of FID-022 in Participants With Advanced Solid Tumors	PHASE1	RECRUITING
A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants	PHASE1	COMPLETED
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors	PHASE1	COMPLETED
Irinotecan in Treating Asian Patients With Solid Tumors	PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy	nan	RECRUITING
Escalated Dose of Irinotecan in mCRC	nan	COMPLETED
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C	nan	COMPLETED
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants	nan	COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a UGT1A4 binder may also engage these)

Protein	Name	Similarity
P35504	—	1.000	P35504 →
UGT1A3	UDP-glucuronosyltransferase 1A3	1.000	landscape →
Q64637	—	1.000	Q64637 →
Q64550	—	1.000	Q64550 →
Q64638	—	1.000	Q64638 →
Q28612	—	1.000	Q28612 →
P20720	—	1.000	P20720 →
UGT1A1	UDP-glucuronosyltransferase 1A1	0.999	landscape →
P70691	—	0.999	P70691 →
P08430	—	0.998	P08430 →
Q64435	—	0.996	Q64435 →
Q63886	—	0.996	Q63886 →
UGT1A6	UDP-glucuronosyltransferase 1A6	0.993	landscape →
Q28611	—	0.991	Q28611 →
Q6ZQM8	—	0.986	Q6ZQM8 →
Q64634	—	0.985	Q64634 →
Q64633	—	0.981	Q64633 →
Q62452	—	0.979	Q62452 →
P36510	—	0.970	P36510 →
Q80X89	—	0.969	Q80X89 →
Q6PDD0	—	0.968	Q6PDD0 →
P36512	—	0.967	P36512 →
P0DTE5	—	0.966	P0DTE5 →
Q9R110	—	0.965	Q9R110 →
O02663	—	0.965	O02663 →
P54855	—	0.963	P54855 →
Q8BWQ1	—	0.963	Q8BWQ1 →
UGT2B17	UDP-glucuronosyltransferase 2B17	0.963	landscape →
O19103	—	0.962	O19103 →
Q8WN97	—	0.962	Q8WN97 →